Professor of Psychiatry, Dr. Marcus Heilig, and BrainsWay CEO, Yaacov Michlin, report on the comparatively stronger MDD response and remission rates from the use of BrainsWay Deep TMS in conjunction with medication.
Mass Device Highlights First Independent Head-to-Head TMS Study
Comments